EUVIMEDEUVIMED entdecken
Crossref

Targeting myeloid differentiation protein 2 ameliorates rheumatoid arthritis by inhibiting inflammation and ferroptosis via MAPK and NF-κB signaling pathways

Lirun Zhou, Tong Yang, Shujie Zhang, Dandan Liu, Chenran Feng, Jiang Ni, Qiaoli Shi, Yanqing Liu, Yuqing Meng, Yongping Zhu, Huan Tang, Jigang Wang und 1 weitere

Journal of Molecular Medicine · 2025

DOI: 10.1007/s00109-025-02555-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Molecular Medicine, 2025. Verfasst von Lirun Zhou und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-Di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica,…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, NF-kappa B, Ferroptosis, Lymphocyte Antigen 96. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China under grants, Non-profit Central Research Institute Fund of the Chinese Academy of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myeloid differentiation protein 2 (MD2), a co-receptor of toll-like receptor 4 (TLR4) in the innate immune system, has emerged as a promising target for anti-inflammatory therapies. Rheumatoid arthritis (RA), a chronic autoimmune disorder characterized by persistent synovial inflammation and progressive joint destruction, remains a therapeutic challenge due to the lack of effective treatment options. In this study, we investigated the role of MD2 in the pathogenesis and progression of RA. Our findings show that MD2 is overexpressed in both the whole blood and synovial tissues of RA patients. Furthermore, MD2 expression was upregulated in collagen-induced RA mouse models. MD2 knockout significantly alleviated key symptoms of RA, including improved body weight, reduced paw swelling, and decreased bone destruction and cartilage erosion. Additionally, MD2 deficiency led to a significant reduction in serum levels of inflammatory cytokines and a decrease in the expression of inflammatory protein within synovial tissue. Notably, animal models revealed that genetic ablation of MD2 exerts potent anti-ferroptosis effects in arthritic pathophysiology. This protective effect was recapitulated at the cellular level through pharmacological interventions, where MD2-targeting inhibitors effectively attenuated lipopolysaccharide-induced ferroptotic cell death in murine macrophages, as evidenced by characteristic biomarkers including glutathione depletion and lipid peroxidation. Mechanistically, the reduction in ferroptosis and inflammation following MD2 knockout was associated with the inhibition of mitogen-activated protein kinase (MAPK) and nuclear factor kappa-B (NF-κB) signaling pathways in the synovial tissue. These results suggest that MD2 plays a critical role in both the inflammatory response and ferroptosis, in the context of RA. Consequently, MD2 represents a key mediator of RA pathogenesis and an innovative therapeutic target for the treatment of this debilitating disease. KEY MESSAGES: MD2 expression is upregulated in synovial tissue following the onset of rheumatoid arthritis. MD2 knockout alleviates bone destruction, cartilage erosion, and inflammation in rheumatoid arthritis mice. MD2 deficiency mitigates rheumatoid arthritis in mice by inhibiting ferroptosis induced by the MAPK and NF-κB signaling pathways. MD2 may serve as a potential therapeutic target for rheumatoid arthritis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidNF-kappa BFerroptosisLymphocyte Antigen 96InflammationMAP Kinase Signaling SystemAnimalsMiceHumansSignal TransductionMice, KnockoutMaleDisease Models, AnimalArthritis, ExperimentalMitogen-Activated Protein KinasesSynovial Membrane

Stichwörter der Autor:innen

Collagen-induced arthritisFerroptosisInflammationMAPKMyeloid differentiation-2NF-κBRheumatoid arthritis

Substanzen

NF-kappa BLymphocyte Antigen 96Ly96 protein, mouseLY96 protein, humanMitogen-Activated Protein Kinases

Autor:innen und Institutionen

  • State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-Di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
  • Department of Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi, 214000, P.R. China.
  • State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-Di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China. ht…
  • State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-Di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China. jg…
  • State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-Di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China. am…

Förderung

  • National Natural Science Foundation of China under grants
  • Non-profit Central Research Institute Fund of the Chinese Academy of Medical Sciences

Zitieren

APA

Zhou, L., Yang, T., Zhang, S., Liu, D., Feng, C., Ni, J., Shi, Q., Liu, Y., Meng, Y., Zhu, Y., Tang, H., Wang, J., & Ma, A. (2025). Targeting myeloid differentiation protein 2 ameliorates rheumatoid arthritis by inhibiting inflammation and ferroptosis via MAPK and NF-κB signaling pathways. Journal of Molecular Medicine. https://doi.org/10.1007/s00109-025-02555-8

Vancouver

Zhou L, Yang T, Zhang S, Liu D, Feng C, Ni J, et al. Targeting myeloid differentiation protein 2 ameliorates rheumatoid arthritis by inhibiting inflammation and ferroptosis via MAPK and NF-κB signaling pathways. Journal of Molecular Medicine. 2025. doi:10.1007/s00109-025-02555-8

BibTeX
@article{Zhou2025,
  author = {Zhou, Lirun and Yang, Tong and Zhang, Shujie and Liu, Dandan and Feng, Chenran and Ni, Jiang and Shi, Qiaoli and Liu, Yanqing and Meng, Yuqing and Zhu, Yongping and Tang, Huan and Wang, Jigang and Ma, Ang},
  title = {Targeting myeloid differentiation protein 2 ameliorates rheumatoid arthritis by inhibiting inflammation and ferroptosis via MAPK and NF-κB signaling pathways},
  journal = {Journal of Molecular Medicine},
  year = {2025},
  doi = {10.1007/s00109-025-02555-8}
}
Kostenlos starten →